Discover how our strategic approach transforms the discovery and development of oncology treatments.
Unlike companies with broad disease models, Carcinotech's laser focus on oncology keeps us at the forefront of cancer research. This allows us to dedicate resources to advancing our technology, expanding our bank of biopsies, optimizing assays, and supporting diverse cancer modalities.
Our specialization also enables us to offer exceptional customization and in-house expertise, making us the ideal partner for drug developers and healthcare providers seeking innovative oncology solutions.
We've spent a lot of time optimizing our models to preserve cancer heterogeneity, incorporating diverse cell types from patient biopsies, including immune populations for more accurate testing.
Our fully automated bioprinting process ensures precise control of tumor structure, ensuring uniformity and reproducibility. This provides strong experimental control for better clinical translation, driving more relevant and reliable outcomes in cancer research.
We offer a comprehensive solution that integrates every aspect of your project. Our end-to-end services include biopsy collection, advanced bioprinting, project design, and specialized assay expertise.
By partnering with us, we help streamline processes, bridge resource gaps, and provide expert guidance, ensuring faster, more efficient research outcomes.
Carcinotech’s dedication to accelerating drug discovery and development is reflected in its straightforward fee-for-service payment model.
Therapeutic developers can readily access Carcinotech’s solution without the complexities of a license-based model.
